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Abstract: 
Background: Diabetes mellitus (DM) is considered to be associated with risk of pancreatic cancer, however, 
whether DM is a cause or a result of PaC is still controversial. We examined this association and mortality rate of 
pancreatic cancer due to DM by conducting a detailed meta-analysis of cohort studies.  
Methods: Studies were identified by searching Medline and Embase. By using a random effect model summary 
relative risk were calculated with 95% confidence interval. 
 Results: thirty-five cohort studies were selected in this meta-analysis. High risk of Pac  (the summary RRs = 1.94; 
95% CI, 1.66–2.27), with evidence of heterogeneity among these studies (p < 0.001, I 2 = 93.6%).  In addition, the 
relative risk of PaC was correlated negatively with the duration of DM, with the highest risk of PaC found among 
patients diagnosed within less than 1 year.  
Conclusions: Findings from this meta-analysis strongly support that diabetes is associated with an increased risk of 
PaC in both males and females and that DM is both an early manifestation and an etiologic factor of pancreatic 
cancer. The death rate from pancreatic cancer was doubled in diabetics.  
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INTRODUCTION: 
Diabetes mellitus and pancreatic cancer are known to 
be associated, but it is not known whether diabetes is 
a true risk factor, preceding development of the 
cancer, or if it is an early manifestation of the cancer. 
[1] Pancreatic cancer (PaC) carries a dismal 
prognosis with a 5-year survival rate of less than 5%, 
and for most patients, death occurs within 6 months 
after diagnosis of cancer. [2] Although cancer of the 
pancreas accounts for only 3% of all cancers 
worldwide its poor prognosis makes it the eighth 
major form of cancer-related death worldwide, 
causing more than 220 000 deaths annually. Apart 
from cigarette smoking, which has been estimated to 
cause about 30% of pancreatic cancers relatively little 
is known about the other chief determinants of the 
disease, although other lifestyle factors have been 
implicated, including obesity and type-II diabetes.3 
Increasing age is strongly associated with the 
elevated risk of PaC, with less than 10% of cases 
occurring in individuals <50 years of age. [4] 
Cigarette smoking is the only generally accepted 
modifiable risk factor, but explains only 25–29% of 
pancreatic cancer incidence. 
Curative resection offers the only chance of cure, but 
at the time of diagnosis, only 10–20% patients are 
fortunate enough to undergo tumors resection. Most 
patients are present with locally advanced or 
metastatic disease and thus are not eligible for 
curative surgery. To improve the survival rate of 
pancreatic cancer, therefore, identification of 
individuals at high risk for pancreatic cancer could 
have a marked impact on reducing morbidity and 
mortality.  
Diabetes mellitus (DM) is considered to be one of the 
major public health challenges in both industrialized 
and developing countries. A number of studies have 
found that DM may alter risk of a variety of cancers, 
including cancers of the breast, [5] pancreas, [6] and 
liver. [7] Several biological mechanisms have been 
indicated to explain the potentially causal relationship 
between DM and risk of cancer. It is suggested that 
abnormal metabolic, immunologic and hormonal 
characteristics of DM may promote cancer 
development. In addition, insulin resistance and 
subsequent hyperinsulinemia may up-regulate the 
production of insulin-like growth factor-1 (IGF-1), 
which may result in enhanced cell proliferation and 
promote cancer development. [8] Specially, 
associations between DM and the development of 
PaC have been well-established; at the time of 
diagnosis, nearly 80% of PaC patients have either 
impaired glucose tolerance or evident DM. [9] 
However, it is not yet determined whether diabetes is 
a predisposing factor or a possible consequence of 
tumor development, or both. [10] 
METHODOLOGY:  
Data sources: 
Relevant studies were identified through EMBASE, 
PUBMED and MEDLINE using a combined text 
word and MESH heading search strategy of 
pancreatic cancer (pancreas, tumor, malignancy) and 
type-II diabetes (NIDDM, diabetes, adult-onset 
diabetes). References from identified studies, as well 
as from the previous review, were also scanned to 
identify any other relevant studies. 
 
Inclusion and exclusion criteria 
Studies were included in the meta-analysis if they had 
a cohort or nested case control design; one of the 
exposure interests was DM; one of the outcome of 
interests was pancreatic cancer and; rate ratio, hazard 
ratio or standardized incidence/mortality rate 
(SIR/SMR) with their 95% CIs (or data to calculate 
them) were reported. Studies were excluded if they 
provided only an effect estimate with no means to 
calculate a CI. In the event of multiple publications 
from the same population or cohort, we included only 
data from the most recent report or the publication 
with the most control for confounders. By these 
criteria, three articles were excluded from our 
metaanalysis. [11-13] we excluded two cohort studies 
containing patients with potential type 1 diabetes, 
which was defined as DM onset at early age (630 
years). We also excluded one cohort study which 
presented with the association of gestational diabetes 
and risk of PaC. 
 
Study analysis: 
Studies that reported separate ORs for mutually 
exclusive categories of duration since diabetes was 
diagnosed (e.g. 1 –4 years, 5 –9 years, 410 years) 
were pooled separately to examine how the strength 
of the association varied with duration of diabetes. 
Possible sources of heterogeneity were investigated 
by comparing the results for studies combined with 
respect to particular characteristics (e.g. sex, method 
of diagnosis of diabetes). All analyses were 
performed using STATA, version 8. 
RESULTS AND DISCUSSION: 
A total of thirty-five cohort studies, which met the 
inclusion and exclusion criteria, were used in this 
meta-analysis (Tables 1 and 2). Of these 35 studies, 
27 studies employed incidence and/or mortality rates 
as the measurement of relative risk. And 8 cohort 
studies used SIR/SMR as the measurement of relative 
risk.  
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The 27 cohort studies, which used incidence or 
mortality rate as the measurements of relative risk, 
comprised between 251 and 1,298,385 persons with a 
median follow-up period of 8.1 years (ranged 2.8–25 
years). Most cohorts included in this meta-analysis 
were apparently healthy population, and only three 
studies included a special population: familial 
pancreatic cancer kindreds,38 patients with a history 
of cholecystectomy and HCV-carriers. Most of the 
studies included both men and women, and four 
studies consisted entirely of men and 1 study 
consisted entirely of women. Eight studies 
comprising persons (range: 1135– 134,096) reported 
risk estimates of cohorts with T2DM. After a median 
follow-up period of 10 years (ranged 5.2–18 years), 
1919 patients were found to be afflicted with 
pancreatic cancer. 
Among these 35 studies, only 4 studies did not 
demonstrate a significantly increased risk of 
pancreatic cancer in patients with 
diabetes,38,48,52,53, and the rest 31 studies reported 
a significantly increased risk of PaC in diabetic 
individuals. DM was determined on the basis of a 
positive history (n = 23); the remaining were based 
on the following: fasting or postprandial glucose test 
(n = 4); medical records (n = 7); not indicated clearly 
(n = 1). 
 
 
DM and PaC risk: 
As shown in Fig. 1, the summary RR with 95% CI 
was 1.94(95% CI, 1.66–2.27) in a random-effects 
model for individuals with diabetes compared with 
individuals without diabetes or general population. 
Though there was significant heterogeneity among 
these studies (p < 0.001, I 2 = 93.6%), all risks were 
above unity. Fifteen studies provided results on 
cancer risk specific for both sexes, and three studies 
consisted entirely of men, one study consisted 
entirely of women. In stratified analysis by sex, 
diabetes was associated with an increased risk of PaC 
in both males and females [summary RRs (95%CI), 
1.70(1.55– 1.87) in males and 1.60(1.43–1.77) in 
females. 
 
Duration of DM and PaC risk: 
The temporal sequence between diabetes and 
pancreatic cancer has not always been clear. Duration 
of diabetes in four studies were similar across the 
studies: 1–4 years, 5–9 years and >10 years,34,49–51 
one study presented with RRs for duration of diabetes 
categorized for each year between the 1st and 6th 
year, and three studies for less than 1 year. 
Combining these studies according to diabetes 
duration, respectively, we found that individuals with 
the shorter duration of diabetes (1–4 years) had 
higher risk of developing pancreatic cancer than 
individuals who had duration of diabetes between 
5years to 9 years. 
 
Mortality rate:  
 
 
 
 
 
Table 3. Eligible cohort for analysis, Cancer Prevention Study II, United States, 
 
Total Pancreatic                                                         Total Pancreatic 
 
  cancer deaths  cancer deaths 
     
Initial cohort 
Exclusions 
676,306 1,666 508,353 1,813 
Died within ®rst year of study 2,673 51 4,732 85 
Missing race 3,271 6 2,397 7 
Prevalent cancer 56,846 220 25,154 157 
Analytic cohort 613,516 1,389 476,070 1,564 
Diabetics 27,059 108 26,769 141 
No. of women No. of men  
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Table 2 – Characteristics of eight cohort studies of diabetes and pancreatic cancer based on standardised incidence/mortality 
ratio. 
 
Author/ 
publication 
years(country) 
Year of 
study 
conduct
ed 
No. of 
subjects 
Demographi
cs (age, mean 
years) 
DM 
ascertainment 
Duration 
of DM, 
years 
PaC 
ascertainment 
No. 
of 
Pa
C 
Follo
w up, 
years 
R
Ra 
(95% 
CI) 
Adjustments 
Kwssler/1970/ 
USA47 
 
 
 
1930–
1959 
21,290 Age:40–59, 
Male:44% 
Blood glucose 
test 
>1 Death registry 78 10.2 1.80(1.26– 
2.59)b( both), 
1. 47(1.03 – 
2.10)c( m), 
2. 13(1.62–
2.81)c( f ) 
Age, sex 
Ragozzino/1982/ 
USA48 
1945–
1969 
1,135 Age:61, 
Male:53% 
Blood glucose 
levels 
>1 Histological 
verification 
5 8.6 2. 6(0.9–6.1) 
(both), 
2.70 (0.60–
8.0)(m) , 
2.50 (0.30–
9.5)(f) 
Age, sex 
Adami/1991/ 
Sweden49 
1965–
1984 
51,008 Age:all years, 
Male:45.4% 
Medical 
records 
>1 Cancer 
registry 
156 5.2 1.40(1.2– 
1.7)(both), 
1. 40(1.10–
1.80)(m) , 
1.50 (1.20–
1.80)(f) 
Age, sex 
Chow/1995/ 
Sweden50 
1965–
1989 
134,096 Age:all age, 
Male:47.7% 
Medical 
records 
>1 Medical 
records 
650 6.8 
(M); 
6.7(F) 
1. 93(1.78–
2.08) 
(both), 1.88 
(1.62– 
2. 10)(m) , 
1.97(1.77–
2.19)(f) 
Age, sex, year 
of follow-up 
Wideroff/1997/ 
Denmark51 
1977–
1989 
109,581 Age:64(m); 
69(f), 
Male:49% 
Medical 
records 
>1 Cancer 
registry 
417 17 1.65(1.49– 
1.84)b(both), 
1.7(1.5–
2.0)(m) , 
1.6(1.4–
1.9)(f) 
Age, sex, 
calendar year 
Verlato/2003/ 
Italy52 
1987–
1996 
7148 Age:67, 
Male:50% 
Medical 
records 
NA mortality 
records 
35 10 1.33 (0.93–
1.85) 
(both), 0.90 
(0.46– 1.57) 
(m), 1.78 
(1.13–2.67) ( 
f ) 
Age, smoking, 
BMI, 
Swerdlow/2005/ 
UK53 
1972–
2003 
5066 Age:30–49, 
Male:58.1% 
Self-reported NA Cancer 
registry 
12 18 1.30 (0.67–
2.27) 
Age, sex, 
calendar year, 
residence 
Hemminki/2010/ 
Sweden46 
1964–
2007 
125,126 Age:>39, 
Male:NA 
Medical 
records 
>1 Cancer 
registry 
566 15 3.57(3.28–
3.88) 
NA 
CI, confidence interval; DM, diabetes mellitus; BMI, body mass index; NA, data not applicable; m, 
male; f, female; RR, relative risk. 
a 
The measure of RR is a standardised incidence (or mortality) ratio. 
b 
The RR and 95% CI were derived by pooling the sex-specific SIR/SMR. 
c 
The RR and 95% CI were calculated from the data reported in the article. 
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fig. 1 – Relative risks for the association between diabetes and risk of pancreatic cancer. Studies are sub-grouped 
according to design.study-specific relative risks or summary relative risks with 95% CIs is represented by demonds.; 
horizontal lines tells 95% confidence intervals (CIs). Test for heterogeneity among studies: p < 0.001, I 2 = 93.6%. 
1, cohort studies (n = 27) use mortality rate as the measurements of relative risk. 2, cohort studies (n = 8) used. 
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Cohort and nested case – control studies of diabetes and pancreatic cancer 
                                                       Diabetes PC                                                   among individuals with diabetes 
 
year Cohort source diagnosis Duration follow-up Source cases adjustment Risk 95% 
CI 
Ragozzino, 
1982 
Rochester, US   MR 41 9800 MR, DC 3 M Age, sex 2.70 0.60 – 
9.50 
     2 F  2.50 0.30 – 
18.4 
Whittemore, 
1983 
50 000 students, SR 
Harvard University, US 
46 NA 
 
 
 
 
DC 3 Age 6.08 0.99 – 
47.0 
Rulyak, 2003 251 subjects, SR 
Washington, US 
NA NA MR, P, DC NA Age, 
smoking, 
sex, prior 
history of 
nonPC 
2.10 0.40 – 
10.9 
Hiatt, 1988 122 894, San 
Francisco, US 
SR 45 NA MR, CR 5 Age, sex, 
race, 
smoking, 
alcohol, 
coffee 
4.50 1.20 – 
16.7 
Balkau, 1993 6988 male civil 
servants, France 
OGTT 42 NA MR, P NA Age, smoking 3.60 1.00 – 
13.0 
Shibata, 1994 13 976 Southern 
California 
retirees, US 
SR ¼o4 3057 MR 4 Age, sex, 
smoking 
3.63 1.22 – 
10.8 
Inoue, 2003 200, Japan SR 41 NA MR, CR NA Age, sex, 
family 
history, 
alcohol, 
exercise, diet 
2.07 1.14 – 
3.74 
        1.29 0.46 – 
3.56 
Batty, 2004 18 006 male 
civil servants, 
UK 
OGTT NA NA DC 4 Age, 
employment, 
smoking, 
SBP, 
physical 
activity, 
disease 
history 
3.99 1.44 – 
11.0 
Jee, 2005 1 298 385, 
Korea 
OGTT 41 NA MR, CR NA Age, 
smoking, 
alcohol use 
1.71 1.42 – 
2.06 
        1.71 1.25 – 
2.34 
Lund Nilsen 
2000 
31 000 M SR NA 6181 CR 4 M Age, sex 1.10 0.40 – 
3.00 
 32 374 F, 
Norway 
  8059  3 F  0.80 0.30 – 
2.70 
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Mills, 1988 34 000 
Adventists, 
California 
SR 41 9683 DC 8 Age, sex 3.43 1.47 – 
7.94 
Gapstur, 2000 20 473 M, 15 
183 F, 
Chio 
SR NA NA DC NA Age 2.48 1.20 – 
4.49 
Stolzenberg- 
 
29 084 M, 
Finland 
SR 45 10 669 CR, MR 14 Age, 
smoking, 
occupational 
activity, 
asthma, blood 
pressure 
2.23 1.08 – 
4.60 
Lino, 2002 110 792, Japan SR 41 
20 859 M, 
15 389 F 
DC 17 
Age, sex, and 
smoking 
2.10 
1.20 – 
3.60 
      9  1.50 0.73 – 
3.12 
Friedman, 
1993 
175 000, San 
Francisco 
SR 41 NA MR, CR  Age, weight 2.37 1.46 – 
3.85 
Adami, 1994 1.2 million, 
Sweden 
Hospitalised 
patients 
41 143 618 M CR 68 M Age, sex 1.40 1.10 – 
1.80 
    119 643 F  88 F  1.50 1.20 – 
1.80 
Coughlin, 
2004 
467 922 M, 588 
322 F, 
Columbia and 
Puerto 
Rico 
SR 41 NA DC NA Age, sex, 
race, 
education, 
family 
history, 
BMI, 
smoking, 
alcohol, 
diet history 
1.48 1.27 – 
1.73 
        1.44 1.21 – 
1.72 
Chow, 1995 134 096 hospitalised for 
Hospitalised diabetes, Sweden
 patients 
41 432 643 M CR 303 Age, sex, 
year of 
follow-up 
1.88 1.62 – 
2.10 
   468493 F  347  1.97 1.77 – 
2.19 
Wideroff, 
1997 
109 581 hospitalised for 
Hospitalised diabetes, 
Denmark patients 
41 628 129 MR, CR 417 Age, sex, 
year of 
follow-up 
1.70 1.50 – 
2.50 
       1.60 1.40 – 
2.90 
 
CONCLUSION: 
In summary, the results from this meta-analysis 
strongly support an association between diabetes and 
increased risks of pancreatic cancer in both women 
and men. Diabetes is both a possible risk factor and 
an early manifestation of pancreatic cancer. The 
death rate from pancreatic cancer was double in 
diabetics (adjusted RR = 2.05, CI = 1.56-2.69). 
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